Wonbiogen Co.,Ltd.: debt-to-equity, ROE and more
KOSDAQ, Legal name Wonbiogen Co.,Ltd.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 11.7%
- Equity ratio
- 89.5%
- ROE
- 15.2%
- Op. margin
- 22.5%
- Rev. growth
- 15.8%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩140 | 15.3% |
| 2024 | ₩20 | 12.5% |
| 2023 | ₩10 | 12.9% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 43.2% | 69.8% | -2.5% | 11.5% | n/a |
| FY2022 consolidated | 45.1% | 68.9% | 12.2% | 19.3% | 50.9% |
| FY2023 consolidated | 31.5% | 76.0% | 18.3% | 24.1% | 10.7% |
| FY2024 consolidated | 10.7% | 90.3% | 14.3% | 21.0% | 2.8% |
| FY2025 consolidated | 11.7% | 89.5% | 15.2% | 22.5% | 15.8% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩17.7B | ₩26.7B | ₩29.6B | ₩30.4B | ₩35.2B |
| Operating profit | ₩2.0B | ₩5.2B | ₩7.1B | ₩6.4B | ₩7.9B |
| Pre-tax income | -₩795.5M | ₩3.7B | ₩7.2B | ₩6.4B | ₩7.8B |
| Net income | -₩659.8M | ₩3.3B | ₩6.0B | ₩5.3B | ₩6.5B |
| Total assets | ₩38.0B | ₩38.9B | ₩42.9B | ₩41.3B | ₩47.6B |
| Total liabilities | ₩11.5B | ₩12.1B | ₩10.3B | ₩4.0B | ₩5.0B |
| Total equity | ₩26.6B | ₩26.8B | ₩32.6B | ₩37.3B | ₩42.6B |
| Paid-in capital | ₩3.6B | ₩3.6B | ₩3.7B | ₩3.7B | ₩3.7B |
| Debt/equity (source value) | 43.2% | 45.1% | 31.5% | 10.7% | 11.7% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2018-09-03
- Listed
- 18/12/05
- Employees
- 77
- Auditor
- 정진세림회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101116860442
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 원바이오젠Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.